Skip Navigation


Brain Advance Access originally published online on June 1, 2005
Brain 2005 128(10):2383-2395; doi:10.1093/brain/awh555
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/10/2383    most recent
awh555v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fedele, D. E.
Right arrow Articles by Boison, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fedele, D. E.
Right arrow Articles by Boison, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation

Denise E. Fedele1,2,*, Nicolette Gouder1,*, Martin Güttinger1, Laetitia Gabernet1, Louis Scheurer1, Thomas Rülicke3, Florence Crestani1 and Detlev Boison1,2

1 Institute of Pharmacology and Toxicology, University of Zurich, 2 Institute of Pharmaceutical Sciences, Federal Institute of Technology (ETH) and 3 Biological Central Laboratory, University of Zurich, Zurich, Switzerland

Correspondence to: Detlev Boison, Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland. E-mail: boison{at}pharma.unizh.ch

Adenosine kinase (ADK) is considered to be the key regulator of the brain's endogenous anticonvulsant, adenosine. In adult brain, ADK is primarily expressed in a subpopulation of astrocytes and striking upregulation of ADK in these cells has been associated with astrogliosis after kainic acid-induced status epilepticus (KASE) in the kainic acid mouse model of temporal lobe epilepsy. To investigate the causal relationship between KASE-induced astrogliosis, upregulation of ADK and seizure activity, we have developed a novel mouse model [the Adktm1–/–-Tg(UbiAdk) mouse] lacking the endogenous astrocytic enzyme due to a targeted disruption of the endogenous gene, but containing an Adk transgene under the control of a human ubiquitin promoter. Mutant Adktm1–/–-Tg(UbiAdk) mice were characterized by increased brain ADK activity and constitutive overexpression of transgenic ADK throughout the brain, with particularly high levels in hippocampal pyramidal neurons. This ADK overexpression was associated with increased baseline levels of locomotion. Most importantly, two-thirds of the mutant mice analysed exhibited spontaneous seizure activity in the hippocampus and cortex. This was the direct consequence of transgene expression, since this seizure activity could be prevented by systemic application of the ADK inhibitor 5-iodotubercidin. Intrahippocampal injection of kainate in the mutant mice resulted in astrogliosis to the same extent as that observed in wild-type mice despite the absence of endogenous astrocytic ADK. Therefore, KASE-induced upregulation of endogenous ADK in wild-type mice is a consequence of astrogliosis. However, seizures in kainic acid-injected mutants displayed increased intra-ictal spike frequency compared with wild-type mice, indicating that, once epilepsy is established, increased levels of ADK aggravate seizure severity. We therefore conclude that therapeutic strategies that augment the adenosine system after astrogliosis-induced upregulation of ADK constitute a neurochemical rationale for the prevention of seizures in epilepsy.

Key Words: adenosine; adenosine kinase; epilepsy; astrogliosis; transgenic mice

Abbreviations: A1R = adenosine A1 receptor; ADK = adenosine kinase; DPCPX = 8-cyclopentyl-1,3-dipropyl-xanthine; EPSC = excitatory postsynaptic current; GFAP = glial fibrillary acidic protein; ITU = 5-iodotubercidin; KA = kainic acid; KASE = kainic acid-induced status epilepticus; LCCG1 = (2S,1'S,2'S)-2-carboxycyclopropyl) glycine; NBQX = 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulphonamide; Tg = transgenic

.

Received February 7, 2005. Revised April 29, 2005. Accepted May 6, 2005.


* These authors contributed equally to this work


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Neurosci.Home page
J. Klausnitzer and D. Manahan-Vaughan
Frequency Facilitation at Mossy Fiber-CA3 Synapses of Freely Behaving Rats Is Regulated by Adenosine A1 Receptors
J. Neurosci., April 30, 2008; 28(18): 4836 - 4840.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. Gundlfinger, J. Bischofberger, F. W. Johenning, M. Torvinen, D. Schmitz, and J. Breustedt
Adenosine modulates transmission at the hippocampal mossy fibre synapse via direct inhibition of presynaptic calcium channels
J. Physiol., July 1, 2007; 582(1): 263 - 277.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
T. Li, J. A. Steinbeck, T. Lusardi, P. Koch, J. Q. Lan, A. Wilz, M. Segschneider, R. P. Simon, O. Brustle, and D. Boison
Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants
Brain, May 1, 2007; 130(5): 1276 - 1288.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.